Medical Safety & Global Health
Open Access
ISSN: 2574-0407
+44-20-4587-4809
ISSN: 2574-0407
+44-20-4587-4809
Juan Gerardo Reyes-García
Graduate Studies and Research Section Higher School of Medicine, National Polytechnic Institute Plan of San Luis and Díaz Mirón s/n,
Col. Casco de Santo Tomas Del. Miguel Hidalgo, 11340 Mexico City
Mexico
Research Article
Adverse Events Reported with the Use of Mazindol in Adult Obese Mexican Patients
Author(s): Cecilia Fernández del Valle-Laisequilla, Juan Carlos Huerta-Cruz, Lina Marcela Barranco-Garduño, Juan Rodríguez-Silverio, Héctor Isaac Rocha-González and Juan Gerardo Reyes-GarcíaCecilia Fernández del Valle-Laisequilla, Juan Carlos Huerta-Cruz, Lina Marcela Barranco-Garduño, Juan Rodríguez-Silverio, Héctor Isaac Rocha-González and Juan Gerardo Reyes-García
Background: Obesity is a pandemic disease. Lifestyle modifications as diet and exercise remain as the first-line intervention for obesity; however, many patients fail to attain adequate weight loss and require drug treatment. Mazindol is a short-term useful agent in the treatment of obesity, whose safety profile has not been analyzed in Mexican population.
Objective: The current study was performed to investigate the reports of adverse events, received in the supplier laboratory for 8 years (2009-2016) with the purpose of determine potential issues of safety, related to Mazindol (MZ1®).
Methods: Adverse events were arranged in frequency tables and stratified by intensity and causality. Subgroups of sex, age and BMI with a higher frequency of side-effects were identified, as well as the main comorbidities and co.. View More»
DOI:
10.4172/2574-0407.1000143